MEOBF (Mesoblast) Receipts from Customers: $70.7 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEOBF Mesoblast Ltd MEOBF
60 GF Score
Price $1.90
GF Value $0.16
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Mesoblast Receipts from Customers?

Mesoblast MEOBF 60 Receipts from Customers is $70.7 Mil as of Jun. 2026. GuruFocus rates MEOBF with a GF Score™ of 60/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Mesoblast's Receipts from Customers for the three months ended in Jun. 2026 was $25.8 Mil.

Mesoblast's Receipts from Customers for the trailing twelve months (TTM) ended in Jun. 2026 was $70.7 Mil.

Mesoblast Receipts from Customers Historical Data

* Premium members only.

The historical data trend for Mesoblast's Receipts from Customers can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Receipts from Customers Chart

Mesoblast Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Receipts from Customers
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.98 7.48 6.78 5.70 88.45

Mesoblast Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Receipts from Customers Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 10.32 0.00 34.58 25.84
MEOBF
60GF Score
Mesoblast Ltd MEOBF
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Receipts from Customers Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Receipts from Customers represents payment received from customers in the direct cash flow method.

Receipts from Customers for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $70.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Receipts from Customers of $70.7 Mil mean?
Mesoblast (MEOBF) has a Receipts from Customers of $70.7 Mil as of Jun. 2026. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for Mesoblast and its competitors.
Is Mesoblast's Receipts from Customers too high?
Mesoblast's current Receipts from Customers is $70.7 Mil. Overall, Mesoblast has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Receipts from Customers compare to VRTX and REGN?
Mesoblast's Receipts from Customers of $70.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receipts from Customers for a Biotechnology company?
A good Receipts from Customers depends on the Biotechnology industry context. However, Receipts from Customers should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receipts from Customers mean?
A high Receipts from Customers can signal that a stock is expensive relative to its fundamentals. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for Mesoblast and its competitors. Mesoblast's current Receipts from Customers is $70.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Based on GuruFocus' analysis, Mesoblast (MEOBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.90 — trading 1087.5% above its estimated fair value. The current Receipts from Customers is $70.7 Mil. Mesoblast's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receipts from Customers calculated?
Receipts from Customers is calculated from a company's financial statements. For Mesoblast (MEOBF), the current Receipts from Customers is $70.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mesoblast (MEOBF) Overvalued in 2026?

Based on GuruFocus' analysis, Mesoblast stock appears to be overvalued. The current stock price of $1.90 is trading 1087.5% above its estimated GF Value™ of $0.16. GuruFocus considers Mesoblast to be Significantly Overvalued.

Key valuation signals for MEOBF:

  • Receipts from Customers: $70.7 Mil
  • GF Value™: $0.16 vs. price of $1.90 (1087.5% above fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the MEOBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
60GF Score

Get the complete analysis for MEOBF

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.90
Price
$0.16
GF Value